{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:58:07Z","timestamp":1781179087560,"version":"3.54.1"},"reference-count":14,"publisher":"Scientific Scholar","issue":"04","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":256,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Introduction\u2003Multiple myeloma (MM) in very young patients is uncommon, and no treatment guidelines exist for these patients.<\/jats:p>\n                  <jats:p>Patients and Methods\u2003We performed a retrospective analysis of five very young myeloma patients who underwent tandem autologous hematopoietic stem cell transplantation (HSCT).<\/jats:p>\n                  <jats:p>Results\u2003The median age was 37 years (range = 34\u201340 years). A median of two leukapheresis was performed (range = 1\u20134). The median number of hematopoietic stem cells collected was 5.4 \u00d7 106\/kg (4.4\u20138.2 \u00d7 106\/kg). During first transplant, four patients received melphalan of 200 mg\/m2 and one patient received melphalan of 140 mg\/m2 (due to renal failure) as conditioning regimen. Second transplant conditioning was melphalan of 200 mg\/m2 for one patient and melphalan of 140 mg\/m2 for remaining four patients. Two patients were in complete remission, and two were in very good partial remission and one patient progressed to active disease at the time of tandem autologous bone marrow transplant. All patients developed significant mucositis. Neutrophil and platelet recovery was longer in tandem autologous hematopoietic stem cell transplant. More viral infections were seen in tandem transplant. Day 30 and day 100 mortality was nil.<\/jats:p>\n                  <jats:p>Conclusion\u2003We present data on tandem autologous HSCTs in very young patients with MM in India. Responses continued to improve in this small series.<\/jats:p>","DOI":"10.1055\/s-0041-1727068","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T19:02:37Z","timestamp":1623697357000},"page":"233-235","source":"Crossref","is-referenced-by-count":0,"title":["Tandem Autologous Hematopoietic Stem Cell Transplantation in Very Young Patients with Multiple Myeloma"],"prefix":"10.25259","volume":"09","author":[{"given":"Rahul","family":"Naithani","sequence":"additional","affiliation":[{"name":"Division of Hematology & Bone Marrow Transplantation, Max Super Specialty Hospital, Saket, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Dayal","sequence":"additional","affiliation":[{"name":"Department of Lab Medicine, Max Super Specialty Hospital, Saket, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reeta","family":"Rai","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Max Super Specialty Hospital, Saket, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"issue":"10\/068","key":"ref1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"B GM Durie","year":"2017","journal-title":"Lancet"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/leu.2008.402","article-title":"Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)","volume":"23","author":"E Kastritis","year":"2009","journal-title":"Leukemia"},{"issue":"14","key":"ref3","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"M Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1089\/jayao.2017.0034","article-title":"AYA-myeloma: real-world, single-center experience over last 5 years","volume":"7","author":"U Yanamandra","year":"2018","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","article-title":"Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis","volume":"4","author":"B Dhakal","year":"2018","journal-title":"JAMA Oncol"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"952","DOI":"10.4149\/neo_2018_170511N346","article-title":"Comparison of autologous hematopoietic cell transplantation performed in tandem and in disease relapse in multiple myeloma patients","volume":"65","author":"A Jungova","year":"2018","journal-title":"Neoplasma"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12288-016-0749-9","article-title":"Single versus dual platform analysis for hematopoietic stem cell enumeration using ISHAGE protocol","volume":"33","author":"R Naithani","year":"2017","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbmt.2015.03.002","article-title":"American Society for Blood and Marrow Transplantation. Hematopoietic stem cell transplantation for multiple myeloma: Guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"N Shah","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"ref9","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"InterGroupe Francophone du My\u00e9lome. Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"M Attal","year":"2003","journal-title":"N Engl J Med"},{"issue":"17","key":"ref10","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study","volume":"25","author":"M Cavo","year":"2007","journal-title":"J Clin Oncol"},{"issue":"07","key":"ref11","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3324\/haematol.11168","article-title":"Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial","volume":"92","author":"P Sonneveld","year":"2007","journal-title":"Haematologica"},{"issue":"24","key":"ref12","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"P Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.13994","article-title":"Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial","volume":"173","author":"E K Mai","year":"2016","journal-title":"Br J Haematol"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s12288-018-0951-z","article-title":"Autologous hematopoietic stem cell transplantation for multiple myeloma in India","volume":"34","author":"R Naithani","year":"2018","journal-title":"Indian J Hematol Blood Transfus"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1727068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:12:20Z","timestamp":1781176340000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/tandem-autologous-hematopoietic-stem-cell-transplantation-in-very-young-patients-with-multiple-myeloma\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":14,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2021,6,12]]},"published-print":{"date-parts":[[2020,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1727068","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}